본문으로 건너뛰기
← 뒤로

Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review.

Cancer reports (Hoboken, N.J.) 2026 Vol.9(3) p. e70514

Yong KY, Lim SH, Lau LG, Chew LP

📝 환자 설명용 한 줄

[BACKGROUND] Myeloid sarcoma is a rare solid tumour of immature myeloid precursors occurring in an extramedullary site.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Yong KY, Lim SH, et al. (2026). Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review.. Cancer reports (Hoboken, N.J.), 9(3), e70514. https://doi.org/10.1002/cnr2.70514
MLA Yong KY, et al.. "Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review.." Cancer reports (Hoboken, N.J.), vol. 9, no. 3, 2026, pp. e70514.
PMID 41814874
DOI 10.1002/cnr2.70514

Abstract

[BACKGROUND] Myeloid sarcoma is a rare solid tumour of immature myeloid precursors occurring in an extramedullary site. It often presents significant diagnostic and therapeutic challenges to clinical haematologists.

[CASE] We describe a previously healthy patient who presented simultaneously with hyperleucocytic chronic myeloid leukaemia in chronic phase (CML-CP) and a pelvic myeloid sarcoma (MS). She failed to respond to conventional intensive chemotherapy meant for acute myeloid leukaemia but responded well to a combination of radiotherapy and tyrosine kinase inhibitor. She has remained well and in deep molecular response for the past 10 years.

[CONCLUSION] We report the first case of MS in CML-CP that has achieved 10 years of long-term remission with a combination of radiotherapy and tyrosine kinase inhibitor, without allogeneic stem cell transplantation. We also reviewed the literature on CML-CP with simultaneous MS to determine the disease characteristics and treatment outcomes.

MeSH Terms

Humans; Sarcoma, Myeloid; Female; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pelvic Neoplasms; Treatment Outcome; Protein Kinase Inhibitors; Middle Aged; Neoplasms, Multiple Primary; Chemoradiotherapy